Chinanews.com, February 6th. In response to the proposal to include infertility treatment in free medical care, the National Medical Insurance Bureau recently responded that the medical insurance department has always attached great importance to population issues and has included eligible fertility support drugs, such as bromocriptine. , Triptorelin, Clomiphene and other ovulation-stimulating drugs are included in the scope of medical insurance payment, which improves the level of drug protection for some patients.
In August 2022, with the approval of the State Council, 17 departments including the National Health and Health Commission and the National Medical Insurance Bureau issued the "Guiding Opinions on Further Improving and Implementing Active Fertility Support Measures", proposing to guide local governments to comprehensively consider medical insurance (including maternity insurance) funds. Tolerance, related technical norms and other factors, and
gradually include appropriate childbirth analgesia and assisted reproductive technology projects into the scope of fund payment
.
The picture is from the website of the National Medical Insurance Bureau
The National Medical Insurance Bureau stated that in the next step, it will strengthen communication and coordination with relevant departments, and strive to reduce the medical burden of infertile patients and improve the level of medical security.
The National Medical Insurance Bureau also stated that it is necessary to give full play to the advantages of traditional Chinese medicine and promote the combination of traditional Chinese and Western medicine in the treatment of infertility.
Strengthen the training of Chinese and Western medicine infertility experts.
(China New Finance and Economics)